Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Join the world’s largest meeting of non-alcoholic steatohepatitis stakeholders.
This vitamin treatment has previously been well established as safe and effective for people without the virus.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Donna Cryer advocates for many liver-related conditions as founder and CEO of the Global Liver Institute.
Personal struggles with liver disease led Donna Cryer to advocacy.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Experimental therapy led to weight loss and improved biomarkers of liver health.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
The treatment improved ALT liver enzymes, fat accumulation in the liver, insulin resistance and blood lipid levels.
The new, minimally invasive outpatient procedure targets a part of the small intestine that plays a key role in diabetes.
Well-tolerated insulin sensitizer may play a role in the treatment of fatty liver disease.
Initial 12-week results of a 48-week treatment period showed the drug led to a significant decline in weight and liver enzymes.
Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.